logo-loader

Proactive's Robin Davison publishes fresh research note on Poolbeg Pharma

Published: 21:57 09 Mar 2023 AEDT

Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new report on Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), following the release of selected data from its human volunteer LPS challenge trial for lead molecule POLB 001.

 

Click here to read the latest report

Poolbeg Pharma Plc: Further expansion of AI-based R&D

Proactive research analyst Robin Davidson joined Proactive's Katie Pilbeam to discuss his latest research note on Poolbeg Pharma PLC (AIM:POLB). Davidson said in his note that Poolbeg's deal with the Israeli artificial intelligence (AI)-based biotech CytoReason to conduct a drug discovery...

on 28/3/22